PAVmed Inc. (NASDAQ:PAVM) Short Interest Update

PAVmed Inc. (NASDAQ:PAVM) was the recipient of a significant drop in short interest in March. As of March 15th, there was short interest totalling 272,000 shares, a drop of 14.7% from the February 28th total of 318,700 shares. Approximately 3.8% of the company’s stock are short sold. Based on an average daily volume of 221,500 shares, the short-interest ratio is currently 1.2 days.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in PAVmed stock. First Manhattan CO. LLC. grew its position in PAVmed Inc. (NASDAQ:PAVM) by 16.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 700,000 shares of the company’s stock after purchasing an additional 100,000 shares during the quarter. First Manhattan CO. LLC. owned about 6.32% of PAVmed worth $439,000 at the end of the most recent reporting period. 19.93% of the stock is currently owned by hedge funds and other institutional investors.

PAVmed Price Performance

Shares of NASDAQ PAVM opened at $0.72 on Tuesday. PAVmed has a 1-year low of $0.57 and a 1-year high of $2.43. The business has a fifty day moving average price of $0.71 and a 200 day moving average price of $0.89. The stock has a market capitalization of $7.99 million, a P/E ratio of -0.17 and a beta of 1.19.

Analyst Ratings Changes

Separately, Ascendiant Capital Markets reduced their price objective on shares of PAVmed from $21.00 to $19.00 and set a “buy” rating for the company in a research note on Monday, December 9th.

About PAVmed

PAVmed Inc focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.